Mesenchymal stem cell therapy for type 2 diabetes: mechanisms, clinical evidence, and future directions.
Zarei M.
Clinical Trial on Type 2 Diabetes, Chronic Kidney Disease, Chronic Wound, Immune Modulation, published in Mol Biol Rep (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Mol Biol Rep (2025)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41117868
- DOI
- 10.1007/s11033-025-11133-7
Abstract (original English)
Type 2 diabetes mellitus (T2DM) is a global public-health challenge characterized by insulin resistance, progressive β-cell dysfunction, and chronic low-grade inflammation. Conventional therapies often control glycaemia but do not consistently prevent disease progression or complications. Mesenchymal stem cells (MSCs), derived from bone marrow, adipose tissue, and the umbilical cord, have been investigated for T2DM due to their immunomodulatory and paracrine regenerative properties. Preclinical studies and early-phase clinical trials (2000-2025) have reported modest improvements in glycaemic indices, including mean reductions in HbA1c and decreases in exogenous insulin requirements in some cohorts, rather than the uniform 1-2% reduction previously stated. Signals of benefit have also been described in diabetic complications such as nephropathy and wound healing. However, these findings derive largely from small, heterogeneous studies with short follow-up, and should therefore be interpreted cautiously. Recent strategies to enhance MSC efficacy (for example, genetic modification such as OCN-19 overexpression) show preliminary promise but require more rigorous evaluation. Key challenges that currently limit clinical translation include variability in MSC sources and manufacturing, impaired cell function in the diabetic microenvironment, small and underpowered trials, and limited
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level ASystematic ReviewEurope PMC
Dedifferentiation of Mature Adipocytes and Their Future Potential for Regenerative Medicine Applications
Systematic Review on Type 2 Diabetes, Chronic Wound, published in Biomedicines (2026) — summary generated from the PubMed abstract.
- 2026
Biomedicines - Level ASystematic ReviewEurope PMC
Consolidating Clinical Insights and Uncovering Novel Regulatory Mechanisms of Exosomal MicroRNAs in Obesity and Metabolic Dysfunction Associated Steatotic Liver Disease: A Systematic Review and Bioinformatics Analysis
Systematic Review on Type 2 Diabetes, Chronic Inflammation, published in Food Sci Nutr (2026) — summary generated from the PubMed abstract.
- 2026
Food Sci Nutr - Level AMeta-analysisEurope PMC
Autologous and allogeneic mesenchymal stem cell-based therapies for diabetes mellitus: A systematic review and meta-analysis
Meta-analysis on Type 2 Diabetes, Immune Modulation, published in World J Stem Cells (2025) — summary generated from the PubMed abstract.
- 2025
World J Stem Cells1 citations - Level ASystematic ReviewPubMed
Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.
Systematic Review on Type 2 Diabetes, published in Curr Issues Mol Biol (2025) — summary generated from the PubMed abstract.
- 2025
Curr Issues Mol Biol - Level AMeta-analysisEurope PMC
Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes
Meta-analysis on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.
- 2025
Front Pharmacol